Chronic Pain study: Probenecid
Official title Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal
ClinicalTrials.gov ID: NCT04939623
What this study is testing
What is Probenecid?
An investigational oral medication being studied for chronic pain and opioid withdrawal symptoms.
Also referred to as Benemid, Probalan.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if probenecid can reduce withdrawal symptoms when people stop or lower their opioid use.
- Who it's for
- Adults who use opioids for chronic pain and may experience withdrawal when their dose is reduced or stopped.
- What's involved
- Participants will receive probenecid and have regular visits for health checks and symptom assessments.
- Time commitment
- The trial lasts several weeks, with multiple clinic visits to monitor safety and withdrawal symptoms.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Adults with chronic pain. Age greater than or equal to 18 years on the day of enrolment.
- people are currently taking a daily opioid pain medication and planning to taper the dose.
- Participants complete at least one voluntary opioid dose reduction in the twelve-week study period.
- Glomerular filtration rate (GFR) \> 50 mL/min
- Capable of providing informed consent
You likely can't join if
- Allergy to probenecid or related drugs
- History of uric acid renal calculi, if known to be urate calculi. If unknown type, then any history of renal calculi.
- Known G6PD deficiency
- Active gout in any joint
- Penicillins, specifically ampicillin, penicillin G sodium, and piperacillin
- Carbapenems, specifically doripenem and meropenem
See the full eligibility criteria
- Adults with chronic pain. Age greater than or equal to 18 years on the day of enrolment.
- people are currently taking a daily opioid pain medication and planning to taper the dose.
- Participants complete at least one voluntary opioid dose reduction in the twelve-week study period.
- Glomerular filtration rate (GFR) \> 50 mL/min
- Capable of providing informed consent
- Allergy to probenecid or related drugs
- History of uric acid renal calculi, if known to be urate calculi. If unknown type, then any history of renal calculi.
- Known G6PD deficiency
- Active gout in any joint
- Penicillins, specifically ampicillin, penicillin G sodium, and piperacillin
- Carbapenems, specifically doripenem and meropenem
- Lorazepam, midazolam, nitrazepam
- Ketorolac
- Oseltamivir
- Methotrexate
- Mycophenolate
- Current use of drugs which may mask symptoms of withdrawal: a. Clonidine, lofexidine, tizanidine
- Current use of drugs which may diminish the effect of probenecid: a. High dose salicylates including greater than 325 mg PO daily of acetylsalicylic acid (ASA)
- Pregnancy or breastfeeding
- Any major comorbid medical condition which might impair follow-up or result in a safety risk to the participant
- Participation in another clinical trial investigating a drug, medical device, or a medical procedure during the 30 days prior to enrolment. \-
The study team makes the final eligibility decision.
Where it is enrolling
- Calgary, Alberta, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Calgary, Alberta, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.